Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, Silvia Novello, Joachim von Pawel et al.|The Lancet Oncology|2014

Cited by 948